ACADIA Pharmaceuticals Inc (ACAD)
15.08
+0.08
(+0.53%)
USD |
NASDAQ |
May 31, 16:00
15.08
0.00 (0.00%)
After-Hours: 20:00
ACADIA Pharmaceuticals Cash from Financing (TTM): 24.71M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 24.71M |
December 31, 2023 | 25.13M |
September 30, 2023 | 21.31M |
June 30, 2023 | 8.845M |
March 31, 2023 | 7.198M |
December 31, 2022 | 8.199M |
September 30, 2022 | 10.95M |
June 30, 2022 | 11.73M |
March 31, 2022 | 12.90M |
December 31, 2021 | 18.16M |
September 30, 2021 | 31.92M |
June 30, 2021 | 42.57M |
March 31, 2021 | 84.97M |
December 31, 2020 | 81.00M |
September 30, 2020 | 105.93M |
June 30, 2020 | 414.18M |
March 31, 2020 | 371.42M |
December 31, 2019 | 371.85M |
September 30, 2019 | 629.39M |
June 30, 2019 | 309.64M |
March 31, 2019 | 307.94M |
December 31, 2018 | 306.65M |
September 30, 2018 | 10.84M |
June 30, 2018 | 18.52M |
March 31, 2018 | 22.58M |
Date | Value |
---|---|
December 31, 2017 | 31.19M |
September 30, 2017 | 30.38M |
June 30, 2017 | 248.56M |
March 31, 2017 | 262.31M |
December 31, 2016 | 533.81M |
September 30, 2016 | 539.16M |
June 30, 2016 | 314.21M |
March 31, 2016 | 296.05M |
December 31, 2015 | 14.50M |
September 30, 2015 | 7.977M |
June 30, 2015 | 8.127M |
March 31, 2015 | 7.248M |
December 31, 2014 | 203.85M |
September 30, 2014 | 201.67M |
June 30, 2014 | 201.36M |
March 31, 2014 | 309.52M |
December 31, 2013 | 111.68M |
September 30, 2013 | 202.29M |
June 30, 2013 | 208.17M |
March 31, 2013 | 98.36M |
December 31, 2012 | 98.17M |
September 30, 2012 | 7.036M |
June 30, 2012 | 0.166M |
March 31, 2012 | 0.156M |
December 31, 2011 | 13.94M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
7.198M
Minimum
Mar 2023
629.39M
Maximum
Sep 2019
129.60M
Average
28.53M
Median
Cash from Financing (TTM) Benchmarks
Regulus Therapeutics Inc | 105.73M |
Amylyx Pharmaceuticals Inc | 2.634M |
Alnylam Pharmaceuticals Inc | 154.67M |
Cassava Sciences Inc | 24.66M |
Oragenics Inc | 2.096M |